"Canterbury Urology Research Trust is a charitable trust established in 1997"

Based in Christchurch, New Zealand, we conduct high quality research for international Urology clinical trials

About

Canterbury Urology Research Trust is a charitable trust established by a group of urologists in 1997. CURT is a dedicated research centre based in Christchurch, New Zealand conducting national and international clinical Urology trials in conjunction with Urologists nationwide. We have access to a population of 560,000 locally in Canterbury, and 4.3 million around New Zealand.

The aim of the trust is to improve the care of urological patients primarily through research but also by assisting with professional development for nurses. Grants are available for attending seminars and conferences, and our annual Urology Interest Group day.

Read More

Donate

Although many of our trials are sponsored by pharmaceutical companies, Canterbury Urology Research Trust relies on your generosity to allow us to do our own research here in Christchurch.

A gift to CURT is a legacy that lasts beyond one’s lifetime, and helps to further the field of Urology. Your support will allow us to continue to do more life changing research.

Because we are a charitable trust, all donations are tax deductible up to the level of your income.

Read More

Our Trials

Currently recruiting:

Overactive Bladder

Canterbury Urology Research Trust are currently recruiting subjects for a new device for Overactive Bladder(OAB)

The Principal Investigator for this study is Dr Sharon English

This study looks at the use of the Valencia Technologies eCoin system to stimulate the tibial nerve. The device is approximately the size of a New Zealand 50 cent coin. It is implanted under the skin just above the ankle bone. This will give small electrical impulses into the nerve in an attempt to improve or restore normal control of your bladder.

Inclusion Criteria includes:

  • Women and Men 18 years or older
  • Overactive bladder with urgency and incontinence for at least 6 months
  • Is currently on or has tried medication for OAB
Contact us for more information

 

Prostate Cancer (metastatic)

The objective of this phase III study is to determine the benefit of Enzalutamide plus hormone deprivation therapy compared to placebo plus hormone deprivation.

The Principal Investigator for this study is Dr Nicholas Buchan

Eligibility criteria includes:

  • Diagnosis of metastatic prostate cancer
Contact us for more information

Past trials

If you would like more information about any of our trials, please feel free to contact us.

 

Click on the name of the trial for more information (please note currently only some trials have more information).

Read More